US · Healthcare · Health Information Services
EPS came in at 0.08 against a street estimate of -0.60 — a beat of 113.3%.
Analysts rate Schrodinger Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $25.57.
| Fund | Stake |
|---|---|
| BlackRock Inc | 14.07% |
| Gates Bill & Melinda Foundation | 9.33% |
| Rubric Capital Management LP | 8.56% |
| Vanguard Portfolio Management, LLC | 5.06% |
| Amova Asset Management Americas, Inc | 3.62% |
| Sumitomo Mitsui Trust Group Inc | 3.62% |
| Vanguard Capital Management, LLC | 3.60% |
| State Street Corp | 3.07% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SCHRÖDINGER, INC. - Q2 2026 FORM 10-Q SUMMARY --- HEADLINE NUMBERS • Total revenues (6 months ended June 30, 2026): $117,476 thousand ($117.5 milli | 2026-08-05 |
| Results announced · Q3 2026 SCHRÖDINGER Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • ACV (Annual Contract Value): $29.6 million in Q2 2026, up 27% year-over-year; trail | 2026-08-05 |
| Reg FD disclosure · Q2 2026 SCHRODINGER, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received approximately $57 million in cash from Eli Lilly and Company's acquisition | 2026-06-29 |
| Board / officer change · Q2 2026 SCHRODINGER, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 22, 2026 • 3,000,000 additional shares approved for iss | 2026-06-23 |
| Board / officer change · Q2 2026 SCHRODINGER, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Executive Separation Cost: Total severance package valued at approximately $88,096 in bonus | 2026-06-08 |
| Quarterly report · Q1 2026 SCHRÖDINGER, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $58.6 million (Q1 2025: $59.6 million) – essentially flat year-o | 2026-05-05 |
| Proxy statement · Q2 2026 SCHRÖDINGER, INC. – 2026 ANNUAL MEETING PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Election of Directors): Vote to elect three | 2026-04-28 |
| Annual report FY2025 SCHRÖDINGER, INC. - 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Schrödinger, Inc. (NASDAQ: SDGR), physics-based computational drug | 2026-02-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Received $57M from Eli Lilly's acquisition of co-founded Ajax Therapeutics Eli Lilly completed its acquisition of Ajax Therapeutics, a company co-founded by Schrödinger, Inc. As a result of this transaction, Schrödinger received an immediate cash payment of approxi | 2026-06-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Schrodinger Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.